{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021769","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.326208+00:00","generated_at":"2026-06-15T02:29:18.354653+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside terminates Cowen ATM facility, enters new up to $50M at-the-market equity deal with Cantor","bullets":["Terminated prior Cowen Sales Agreement effective May 12, 2023; $35.8M net raised from ~19M shares since 2017.","Entered new Controlled Equity Offering with Cantor Fitzgerald to sell up to $50M of common stock at-the-market.","Cantor will receive up to 3% commission on gross sales; Company not obligated to sell any shares.","New facility provides ongoing equity capital access for the biotech firm."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021769","json":"https://secwatch.observer/filing/0000950170-23-021769.json","markdown":"https://secwatch.observer/filing/0000950170-23-021769.md","text":"https://secwatch.observer/filing/0000950170-23-021769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/clsd-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:29:18.354653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"449cf523a66e839bbb82265a0739408f518f4334","claim":"Clearside Biomedical, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $50 million (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a Controlled Equity Offering SM Sales Agreement (the “ Agreement ”) with Cantor Fitzgerald & Co. (“ Cantor ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Common Stock ”), having an aggregate offering price of up to $50 million through or to Cantor as its sales agent or principal.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"$50 million"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"material_agreement"},{"claim_id":"672937abf79b917dcab62faca5a98d0eadde64f4","claim":"Clearside Biomedical, Inc. terminated Sales Agreement dated June 30, 2017 with Cowen and Company, LLC with Cowen and Company, LLC valued at terminated (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, the Company and Cowen and Company, LLC (“ Cowen ”) agreed to terminate the Sales Agreement, dated as of June 30, 2017, (the “ Prior Sales Agreement ”) between the Company and Cowen, effective as of May 12, 2023 (the “ Termination Date ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cowen and Company, LLC"},{"label":"Value","value":"terminated"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}